# SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance

> **NCT01266148** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 115 (actual)

## Conditions studied

- Renal Function and Chronic Allograft Vasculopathy

## Interventions

- **DRUG:** Cyclosporine
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Corticosteroids
- **DRUG:** Everolimus
- **DRUG:** Anti Thymocyte Globulin

## Key facts

- **NCT ID:** NCT01266148
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2015-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266148, "SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01266148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*